Nautilus Biotech

13 April 2005

Tweet
Facebook
LinkedIn
Google plus
Send to

A syndicate of institutional investors has backed a EUR 7.25m third round of funding to support the development of Nautilus Biotech. The syndicate was led by Auriga Partners, which invested EUR 3m. Previous investors Matignon Technologies, Edmond Rothschild Investment Partners, FCJE, Pre-IPO Invest, 123 Venture and Creabilis Biotech committed the remaining EUR 4.25m. Management own a 15-20% equity stake in the company. Auriga Partners was introduced to the deal by ERIP. The transaction completed in March and took around six months to finalise. Previously, LCF Rothschild Venture Partners and Matignon Technologies committed to a EUR 5.3m first round of financing when the company was founded in 2000. The first round was injected in three separate tranches. In 2003, Matignon Technologies led a E4m second round of institutional funding in Nautilus Biotech. The syndicate included Edmond Rothschild Investment Partners, FCJE, Pre-IPO Invest, 123 Venture and Creabilis Biotech.

Company

Evry-based Nautilus Biotech specialises in improving and developing next generation protein pharmaceuticals. Using its propriety technology, the company has generated a pipeline of improved therapeutic protein molecules with single amino acid substitutions. The firm's lead molecules comprise long lasting interferon alpha and interferon beta, presently in preclinical development. The company plans to use the proceeds to take its lead product, BelerofonÂ® (improved interferon-alpha), into an IND and move its next-generation, long-lasting, non-pegylated interferon-beta into advanced pre-clinical development. The firm was founded in 1999, has a staff of 23 and registered a turnover of EUR 800,000 in 2004.

People

Philippe Peltier led the transaction at Auriga Parnters. Guillaume Connan and RaphaÃ«l Wisniewski coordinated the deal at Matignon Technologies and ERIP respectively. Didier Jardin managed the investment at FCJE, Alain Munoz at 123 Venture and Alain Roubach at Pre-IPO Invest. Manuel Vega is the founder and manager of Nautilus Biotech.